Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

TZTian ZengZZZhikang ZhengJHJian Huang

Discussion

Loading...

Member takes

Overview

Genome-wide CRISPR-Cas9 screen reveals ruxolitinib-resistance genes in myeloproliferative neoplasms, suggesting new therapeutic targets.

Key Points

  • This research aims to identify genetic drivers of ruxolitinib resistance in myeloproliferative neoplasms using CRISPR-Cas9 screening.
  • Performed genome-scale CRISPR-Cas9 knockout screening using the GeCKO library.
  • Utilized SET-2 cell line as a model for myeloproliferative neoplasms.
  • Analyzed genomic DNA from surviving cells via next-generation sequencing after ruxolitinib treatment.
  • Applied bioinformatic tools for identifying enriched and depleted gRNAs associated with genes.
  • Identified 3069 negatively selected genes and 1913 positively selected candidates related to resistance.
  • Essential and resistance-associated genes such as KAT7 and FAM71C were highlighted as significant.
  • GO and KEGG pathway analyses revealed key biological processes related to resistance mechanisms.

Cite This Study

Zeng et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8f2https://doi.org/10.1182/blood-2025-7286
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract B040: Understanding and Overcoming RAS-pathway Mediated Therapeutic Resistance and Disease Progression in Myeloproliferative Neoplasms2026
  2. 2Unravelling molecular determinants of ruxolitinib treatment response in myelofibrosis using single cell multiomics2025 · 1 citations
  3. 3Abstract 7225: Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms2024
  4. 4Abstract 7071: CRISPRi screening identifies epigenetic vulnerabilities and an ARID1A-PRC2 synthetic-lethal axis sensitizing cutaneous T-cell lymphoma to combined JAK/STAT and EZH2 inhibition.2026
  5. 5Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML2025